Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Biofrontera Inc. (BFRI)
Company Research
Source: GlobeNewswire
First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant pCorrelates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics.BCC is the most common skin cancer in the US, with more than 3 million cases each year1. WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, today announced top-line results in its Phase 3 study of the use of Ameluz® with the BF-RhodoLED® lamp in the treatment of sBCC (study ALA-BCC-CT013). The double-blind, randomized, placebo-controlled, multi-center study evaluated safety and efficacy in 187 patients with one or more clinically and histologically confirmed superficial BCCs. They each received one cycle of two PDT treatments (either Ameluz®-PDT or placebo-PDT) 1-2 weeks apart, repeated
Show less
Read more
Impact Snapshot
Event Time:
BFRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BFRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BFRI alerts
High impacting Biofrontera Inc. news events
Weekly update
A roundup of the hottest topics
BFRI
News
- Biofrontera Inc. (NASDAQ: BFRI) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $7.00 price target on the stock.MarketBeat
- Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ... [Yahoo! Finance]Yahoo! Finance
- Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 [Yahoo! Finance]Yahoo! Finance
BFRI
Earnings
- 11/13/24 - Miss
BFRI
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form 10-Q
- BFRI's page on the SEC website